Articles

Find an Article

Filter articles

Applied Filters

Showing 71 to 80 of 309 results

Post-grant proceedings: shaping the biotech landscape

US01-06-2018Jennifer Fox

It is certain that both inter partes and post-grant reviews will continue to shape the landscape for biologics patents and biosimilars, says Jennifer Fox of Brinks Gilson & Lione.

Patent backlog in Brazil: slow, but welcome, progress

Brazil31-05-2018Kene Gallois and Ricardo Nunes

Brazil’s patent backlog has long caused concern for IP owners, particularly those in the pharmaceutical industry, but progress is being made, as Kene Gallois and Ricardo Nunes of Daniel Legal & IP Strategy report.

Can a computer invent a drug?

International, US31-05-2018MaryAnne Armstrong

Artificial intelligence is being used increasingly in the pharma and biotech industries, and questions are being asked about the legal status of innovations created by the technology, as MaryAnne Armstrong of Birch, Stewart, Kolasch & Birch reports.

A growing business: soybeans in Brazil

Brazil29-05-2018Gabriel Di Blasi and Matheus Gil do Amaral

Research and development, strong IP rights and good international relations are all factors in Brazil’s rise as a soybean-producing powerhouse, as Gabriel Di Blasi and Matheus Gil do Amaral of Di Blasi Parente & Associados report.

Clearing a way through the CRISPR patent jungle

Belgium, Denmark, International08-05-2018Timo Minssen, Esther van Zimmeren, Jakob Wested

There may be a path through the CRISPR patent jungle, but there are many obstacles still in the way, say European academics Timo Minssen, Esther van Zimmeren and Jakob Wested.

Eli Lilly: the trials and tribulations of antibody patents

17-04-2018

Courts have not always been able to appreciate the complexities around antibody patents, causing problems for innovation and investment, says Eli Lilly patent counsel Duane Marks in an interview with LSIPR.

AstraZeneca: no time for time-wasting

US08-03-2018

The IP team at AstraZeneca must “ruthlessly” prioritise how it spends time and resources, its vice president of global IP explained in an interview.

Getting into the biosimilars action

US06-03-2018Henk Heus and Ellen Sherin

The financial stakes in the biosimilars market are enormous, and an understanding of sequence IP for the underlying technologies and modes of action is key to entry into it, say Henk Heus and Ellen Sherin of GQ Life Sciences.

The licensing landscape at Pieris

US22-02-2018

Forming licensing agreements with other pharmaceutical companies is an important part of Pieris’s strategy, according to Ahmed Mousa, vice president of licensing, IP and legal affairs at the clinical-stage company.

A helping hand for rare diseases

US08-02-2018

Companies researching and commercialising drugs for rare diseases face unusual challenges in protecting their inventions, as Michael Yamauchi, director and patent counsel at Alexion Pharmaceuticals, tells LSIPR in an interview.

Showing 71 to 80 of 309 results

LSIPR